Clinical Trial Update: Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing immunogenicity and safety of an adjuvanted reduced-dose inactivated polio vaccine used as a booster at 15-18 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Inactivated polio vaccine (adjuvanted, reduced-dose booster)

Snippet

Sponsor: Statens Serum Institut | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED